2021
Potential Schizophrenia Medications Point to New Disease Model
Krystal J. Potential Schizophrenia Medications Point to New Disease Model. Psychiatric News 2021, 56 DOI: 10.1176/appi.pn.2021.11.37.Peer-Reviewed Original ResearchEffects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial
Patel KT, Stevens MC, Dunlap A, Gallagher A, O’Malley S, DeMartini K, Potenza MN, Krystal JH, Pearlson GD. Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial. Neuropsychopharmacology 2021, 47: 840-846. PMID: 34475522, PMCID: PMC8882177, DOI: 10.1038/s41386-021-01157-5.Peer-Reviewed Original ResearchConceptsProtein tyrosine kinasesSrc regulationSrc familyProtein kinaseTyrosine kinaseFyn kinaseSrc inhibitorSrc/FynDependent pathwayKinaseNMDAR upregulationNMDAR functionNMDA receptorsRegulationSaracatinibGluN2B subunitGlutamate receptorsFynInhibitorsReceptorsSubunitsN-methyl-D-aspartate (NMDA) glutamate receptorsPrevious evidenceTranscriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD
Burt JB, Preller KH, Demirtas M, Ji JL, Krystal JH, Vollenweider FX, Anticevic A, Murray JD. Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD. ELife 2021, 10: e69320. PMID: 34313217, PMCID: PMC8315798, DOI: 10.7554/elife.69320.Peer-Reviewed Original ResearchConceptsLysergic acid diethylamideEffects of LSDSerotonin 2A receptorPharmacological neuroimagingNeuromodulatory effectsPharmacological responseFunctional alterationsBrain physiologyCircuit mechanismsFunctional connectivityNeural functionBrain structuresPsychoactive drugsAcid diethylamideFunctional topographyPrecision medicineNeural differencesNeuroimagingAltered statesReceptors
2019
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine’s Antidepressant Effect—Reply
Krystal JH, Yoon G, Petrakis IL. Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine’s Antidepressant Effect—Reply. JAMA Psychiatry 2019, 76: 658-659. PMID: 31042270, DOI: 10.1001/jamapsychiatry.2019.0763.Peer-Reviewed Original Research
2018
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor
Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, Seifritz E, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. ELife 2018, 7: e35082. PMID: 30355445, PMCID: PMC6202055, DOI: 10.7554/elife.35082.Peer-Reviewed Original ResearchConceptsLysergic acid diethylamideLSD effectsResting-state functional connectivityCortical gene expressionHealthy human participantsThalamic connectivityDopamine receptorsReceptor contributionNeurobiological effectsAgonist activityFunctional connectivityBrain connectivityAcid diethylamideReceptorsKetanserinNeuropharmacologyLSD mechanismCritical roleGene expressionAltered statesHuman participantsRational developmentSerotonin
2017
951 Changes in Resting-State Global Brain Connectivity in LSD-Induced Altered States of Consciousness are Attributable to the 5-HT2A Receptor
Preller K, Schleifer C, Stämpfli P, Krystal J, Vollenweider F, Anticevic A. 951 Changes in Resting-State Global Brain Connectivity in LSD-Induced Altered States of Consciousness are Attributable to the 5-HT2A Receptor. Biological Psychiatry 2017, 81: s385. DOI: 10.1016/j.biopsych.2017.02.677.Peer-Reviewed Original Research
2016
The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models
Khlestova E, Johnson JW, Krystal JH, Lisman J. The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models. Journal Of Neuroscience 2016, 36: 11151-11157. PMID: 27807157, PMCID: PMC5148234, DOI: 10.1523/jneurosci.1203-16.2016.Peer-Reviewed Original ResearchConceptsNMDAR antagonistsNMDA receptor hypofunction hypothesisDifferent NMDAR subtypesHealthy human subjectsSymptoms of schizophreniaPsychotogenic effectsNMDA receptorsNMDAR subtypesSchizophrenia modelKetamine's abilityNegative symptomsKetamineMultiple subtypesPsychotic statesPreferential involvementSchizophreniaAntagonistGluN2CSubtypesReceptorsEEG powerHuman subjectsNMDARSymptomsΔ oscillations
2007
The NMDA receptor as a therapeutic target in major depressive disorder.
Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS & Neurological Disorders - Drug Targets 2007, 6: 101-15. PMID: 17430148, DOI: 10.2174/187152707780363267.Peer-Reviewed Original ResearchConceptsMajor depressive disorderNMDA receptorsDepressive disorderNovel antidepressant medicationsCognitive side effectsPotential of drugsAntidepressant medicationAntidepressant propertiesSuch medicationsGlutamatergic neurotransmissionGlutamate receptorsPreclinical studiesPsychotomimetic propertiesSide effectsTherapeutic targetAnimal modelsUseful agentNeurotransmissionReceptorsLines of evidenceMedicationsDisordersDrugsCurrent knowledgeDepression
2006
[I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers
Staley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers. NeuroImage 2006, 31: t154. DOI: 10.1016/j.neuroimage.2006.04.137.Peer-Reviewed Original Research
2005
Alcohol Dependence Is Associated with Blunted Dopamine Transmission in the Ventral Striatum
Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A, Kegeles L, Talbot P, Evans S, Krystal J, Laruelle M, Abi-Dargham A. Alcohol Dependence Is Associated with Blunted Dopamine Transmission in the Ventral Striatum. Biological Psychiatry 2005, 58: 779-786. PMID: 16018986, DOI: 10.1016/j.biopsych.2005.04.044.Peer-Reviewed Original ResearchConceptsAlcohol-dependent subjectsLimbic striatumPositron emission tomographyDopamine transmissionD2 receptorsDopamine releaseAD subjectsAlcohol dependenceAmphetamine-induced dopamine releaseDopamine type 2 receptorHealthy control subjectsD2 receptor availabilityMesolimbic dopamine transmissionType 2 receptorPsychostimulant challengeSensorimotor subdivisionsControl subjectsStriatal subdivisionsAssociative striatumSensorimotor striatumReceptor availabilityStriatumEmission tomographyVentral striatumReceptors
2003
N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability
Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 2003, 99: 79-94. PMID: 12804700, DOI: 10.1016/s0163-7258(03)00054-8.Peer-Reviewed Original ResearchConceptsGlutamatergic systemEthanol abuseGlutamate receptorsN-methyl-D-aspartate (NMDA) subtypePrimary excitatory neurotransmitterAspartate glutamate receptorsAction of ethanolEthanol withdrawalGlutamatergic agentsGlutamatergic functionExcitatory neurotransmitterTranslational neuroscience perspectiveGlutamate systemEthanol intoxicationBehavioral effectsEthanol contributeAlcoholismBrainReceptorsTreatmentAbuseN-methylSubtypesNeurotransmittersIntoxication
1999
Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans
Fujita M, Woods S, Verhoeff N, Abi-Dargham A, Baldwin R, Zoghbi S, Soares J, Jatlow P, Krystal J, Rajeevan N, Charney D, Seibyl J, Innis R. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. European Journal Of Pharmacology 1999, 368: 161-172. PMID: 10193652, DOI: 10.1016/s0014-2999(99)00013-8.Peer-Reviewed Original ResearchConceptsClinical effectsReceptor levelsReceptor densityReceptor occupancyChronic benzodiazepine administrationBenzodiazepine receptor densityHealthy human subjectsComparison of baselineSingle photon emissionHopkins Verbal Learning TestInduced sedationVerbal Learning TestBenzodiazepine administrationOral administrationBaseline valuesBenzodiazepine receptorsTolerance developmentDay 3Day 17Day 4Day 10Central typeLearning TestReceptorsHuman subjects
1997
Benzodiazepine Receptor Antagonists
Abi-Dargham A, Charney D, Krystal J. Benzodiazepine Receptor Antagonists. CNS Drugs 1997, 8: 244-256. DOI: 10.2165/00023210-199708030-00007.Peer-Reviewed Original ResearchBenzodiazepine receptorsIdiopathic recurrent stuporBenzodiazepine receptor antagonistPotential therapeutic benefitBenzodiazepine toleranceCerebral ischaemiaGABAergic systemΓ-aminobutyric acidReceptor antagonistMovement disordersNeuronal markersSleep disordersTherapeutic benefitCognitive disordersPotential treatmentNeuropsychiatric illnessOnly agentInverse agonistFlumazenilPharmacological investigationsAdverse effectsReceptorsDisordersImaging agentEpilepsy